Industry News

FDA Approves Durvalumab + Gemcitabine for Biliary Tract Cancer

 On September 2, 2022, the U.S Food and Drug Administration (FDA) durvalumab in combination with gemcitabine and cisplatin for adult patients with locally advanced or metastatic biliary tract cancer. 

For more information, read the FDA announcement, and the AstraZeneca announcement

Posted 9/8/2022


1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
Email Us